Catecholic butanes and use thereof for cancer therapy
AssigneeTriact Therapeutics, Inc.
InventorsThomas F. White, Edward F. Schnipper, Dan Hoth
Life of this patent
Estimating the term…
Abstract
The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.
Claims6
A method for treating non-small cell lung cancer (NSCLC) in a subject, wherein said subject has developed resistance to treatment with an epidermal growth factor receptor (EGF-R) inhibitor, comprising administering an effective amount of a pharmaceutical composition capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGF-R, wherein the pharmaceutical composition comprises nordihydroguaiaretic acid (NDGA), pharmaceutically acceptable salts thereof or a tautomer thereof.
Dependencies are inferred from the claim text.